← All trials

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

What the trial team says

This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BMS-986504 is given with other anti-cancer agents. The trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of BMS-986504 alone and in combination regimens.

Key facts

Registry number

NCT07492680

Stage of testing

Phase 2

Conditions studied

Solid Tumors

Where it is running

This trial lists 57 sites.

• Barcelona [Barcelona]
  • Local Institution - 0068 (Barcelona)
  • Local Institution - 0071 (Hospitalet)
• Beijing Municipality
  • Local Institution - 0155 (Beijing)
• British Columbia
  • Local Institution - 0051 (Vancouver)
• Bruxelles-Capitale, Région de
  • Local Institution - 0148 (Brussels)
• California
  • Local Institution - 0096 (San Francisco)
• Chongqing Municipality
  • Local Institution - 0185 (Chongqing)
• Colorado
  • Local Institution - 0182 (Aurora)
• Côte-d'Or
  • Local Institution - 0078 (Dijon)
• France
  • Local Institution - 0074 (Paris)
• Georgia
  • Local Institution - 0178 (Atlanta)
• Germany
  • Local Institution - 0040 (Hamburg)
  • Local Institution - 0039 (Heidelberg)
  • Local Institution - 0061 (Leipzig)
  • Local Institution - 0049 (München)
  • Local Institution - 0047 (Würzburg)
• Guangdong
  • Local Institution - 0184 (Guangzhou)
• Henan
  • Local Institution - 0152 (Xinxiang)
• Hong Kong
  • Local Institution - 0150 (Hksar)
  • Local Institution - 0063 (Shatin)
• Hordaland
  • Local Institution - 0171 (Bergen)
• Ireland
  • Local Institution - 0080 (Cork)
  • Local Institution - 0023 (Dublin)
  • Local Institution - 0146 (Dublin)
• Italy
  • Local Institution - 0123 (Bergamo)
  • Local Institution - 0034 (Milan)
  • Local Institution - 0050 (Naples)
  • Local Institution - 0082 (Perugia)
• Maryland
  • Johns Hopkins Hospital (Baltimore)
• Massachusetts
  • Local Institution - 0124 (Boston)
• Michigan
  • Local Institution - 0119 (Ann Arbor)
• Minnesota
  • Local Institution - 0129 (Rochester)
  • Local Institution - 0174 (Rochester)
  • Local Institution - 0181 (Rochester)
• New York
  • Local Institution - 0142 (Buffalo)
  • Local Institution - 0170 (New York)
  • Local Institution - 0139 (New York)
• North Carolina
  • Local Institution - 0100 (Durham)
• Norway
  • Local Institution - 0022 (Oslo)
• Ontario
  • Local Institution - 0021 (Toronto)
  • Local Institution - 0007 (Toronto)
• Oost-Vlaanderen
  • Local Institution - 0114 (Ghent)
• Rhineland-Palatinate
  • Local Institution - 0081 (Mainz)
• Rhône
  • Local Institution - 0075 (Pierre-Bénite)
• Seoul-teukbyeolsi [Seoul]
  • Local Institution - 0004 (Seoul)
  • Local Institution - 0058 (Seoul)
  • Asan Medical Center (Seoul)
• Shanghai Municipality
  • Shanghai GoBroad Cancer Hospital China Pharmaceutical University (Shanghai)
  • Fudan University Shanghai Cancer Center (Shanghai)
• Spain
  • Local Institution - 0033 (Madrid)
  • Local Institution - 0069 (Seville)
• Texas
  • Local Institution - 0085 (Houston)
• Tokyo
  • National Cancer Center Hospital (Chuo-ku)
• Tuscany
  • Local Institution - 0073 (Siena)
• Val-de-Marne
  • Local Institution - 0116 (Villejuif)
• Washington
  • Local Institution - 0086 (Seattle)
• Wisconsin
  • Local Institution - 0134 (Madison)

This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.